EBGLYSS (lebrikizumab) achieves groundbreaking Phase 3 results in children 6 months-18 years with moderate-to-severe atopic dermatitis. 63% achieved EASI-75 skin improvement. Learn about this selective IL-13 inhibitor breakthrough.
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
Pfizer’s investigational trispecific antibody, tilrekimig, met its primary endpoint in a Phase 2 study for atopic dermatitis, showing significant skin clearance and a favorable safety profile.
Roche’s Phase III ALLEGORY trial reveals that Gazyva plus standard therapy helped 76.7% of SLE patients achieve significant clinical improvement. New data published in NEJM highlights Gazyva’s potential to redefine the standard of care in lupus by preventing organ damage and reducing steroid dependency.
Roche’s investigational amylin analog, petrelintide, achieved a statistically significant 10.7% mean body weight reduction in a Phase II trial, offering a well-tolerated alternative to current obesity treatments.
Eli Lilly and Company has announced breakthrough results from ACHIEVE-3, a head-to-head clinical trial that establishes orforglipron as a superior oral GLP-1 receptor agonist for type 2 diabetes management. The investigational medication outperformed oral semaglutide across all primary and key secondary endpoints, delivering clinically meaningful improvements in blood sugar control and weight loss. With FDA obesity approval expected in Q2 2026 and regulatory submissions already filed in over 40 countries, orforglipron represents a significant advancement in cardiometabolic treatment options.
Johnson & Johnson announces groundbreaking long-term clinical data revealing that TREMFYA (guselkumab) maintains sustained clinical, endoscopic, and histologic remission in adults with moderately to severely active ulcerative colitis through 3 years of treatment. The QUASAR long-term extension study demonstrates 80.8% clinical remission and 78.6% mucosal healing rates, setting new standards for inflammatory bowel disease management.
Pfizer announced positive progression-free survival results from BREAKWATER trial Cohort 3, showing BRAFTOVI combined with cetuximab and FOLFIRI achieves statistically significant and clinically meaningful progression-free survival improvement compared to chemotherapy alone in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.
Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.
Pfizer’s investigational “ultra-long-acting” GLP-1 receptor agonist, PF-08653944, showed robust 12.3% weight loss in its Phase 2b VESPER-3 study. Transitioning from weekly to a once-monthly injection, the drug maintained high efficacy and tolerability, positioning Pfizer as a major competitor in the 2026 obesity drug market.
